Medtech Convergence Fund

The Medtech Convergence Fund (MCF) is a $90 million early-stage venture capital fund managed by SV Health Investors, dedicated to investing in innovative medical device and technology-enabled service companies. MCF's investment strategy centers on the convergence of advanced materials science, component miniaturization, sensors, software, telecommunications, and new delivery models to address significant healthcare challenges. The fund aims to transform the healthcare industry by supporting technologies that shift care from hospitals to home settings, enhance patient access through telehealth, and improve chronic disease management.

MCF's investment approach emphasizes three key areas: investing in passionate, skilled, and patient-centric entrepreneurs with a deep understanding of the healthcare problems they aim to solve; focusing on early-stage, novel device and technology solutions that are differentiated in usability and outcomes, with meaningful barriers to entry through intellectual property, design, and clinical data; and targeting technologies that enable a shift in care to lower acuity and cost settings, leveraging data to improve treatment effectiveness and utilizing communication technologies that link physicians to patients in home settings.

The fund's team comprises experienced professionals, including Managing Partners Paul LaViolette and Greg Madden, and Partner Aaron Sandoski. MCF's strategic limited partner, Teijin Limited, a global technology-driven group, shares the fund's vision of developing disruptive, cost-saving healthcare solutions. Teijin's investment in MCF reflects its commitment to early-stage innovation and its focus on healthcare solutions that enable people to live healthier, happier, and more fulfilling lives. MCF's portfolio includes companies like CarePredict, which received a $29 million Series A-3 investment co-led by MCF and Aspire Healthtech Partners, and Perfuze, which raised $25 million in a Series A funding round with participation from MCF. These investments highlight MCF's dedication to supporting innovative companies that aim to improve patient outcomes and healthcare efficiency.